# Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

> **NCT01457339** · PHASE1 · COMPLETED · sponsor: **Shire** · enrollment: 31 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SPD489 (Lisdexamfetamine dimesylate)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01457339
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-21
- **Primary completion:** 2012-01-20
- **Final completion:** 2012-01-20
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01457339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01457339, "Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01457339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*